Orally inhaled dihydroergotamine: A review

Headache

Volumn 53, Issue SUPPL.2, 2013, Pages 43-53

  Tepper, Stewart J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Acute treatment; Allodynia; Central sensitization; DHE; Dihydroergotamine; Inhaler; Migraine

Indexed keywords

ACUTE TREATMENT; ALLODYNIA; CENTRAL SENSITIZATION; DHE; DIHYDROERGOTAMINE; INHALER; MIGRAINE;

ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; ANALGESICS, NON-NARCOTIC; ANIMALS; CLINICAL TRIALS AS TOPIC; DIHYDROERGOTAMINE; HUMANS; MIGRAINE DISORDERS; NEBULIZERS AND VAPORIZERS;

EID: 84893944228     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/head.12184     Document Type: Article

References (43)

1. Tfelt-Hansen P, Saxena PR, Ferrari MD. Ergot alkaloids. In: Wolf FA, ed. Handbook of Clinical Neurology, Vol 21, Intoxications of the Nervous System. Part II. Amsterdam: Elsevier; 1995: 61-78.
2. Graham JR, Wolff HG. Mechanism of migraine headache and action of ergotamine tartrate. Arch Neurol Psychiatry. 1938;39: 737-763.
3. Graham Jr. Rectal use of ergotamine tartrate and caffeine alkaloid for the relief of migraine. N Engl J Med. 1954;250: 936-938.
4. Goodell H, Ostfeld AM,Wolff HG.Studies on headache; central versus peripheral action of ergotamine tartrate and its relevance to the therapy of migraine headache. AMA Arch Neurol Psychiatry. 1956;76: 571-577.
5. Friedman MD, Friedman DA. Dihydroergotamine in the treatment of migraine; preliminary clinical observations. Ohio Med. 1945;41: 1099.
6. Hartman MM. Parenteral use of dihydroergotamine in migraine. Ann Allergy. 1945;3: 440-442.
7. Raskin NH. Repetitive intravenous dihydroergotamine as therapy for intractable migraine. Neurology. 1986;36: 995-997.
8. Silberstein SD. The pharmacology of ergotamine and dihydroergotamine. Headache. 1997;37(Suppl.): 15-25.
9. Stevens AA. Modern Materia Medica and Therapeutics. Philadelphia, PA: WB Saunders; 1906: 12.
10. Müller-Schweinitzer E. Pharmacologic actions of the main metabolites of dihydroergotamine. Eur J Clin Pharmacol. 1984;26: 699-705.
11. Bigal ME, Tepper SJ. Ergotamine and dihydroergotamine: A review [Sandoz data cited]. Curr Pain Headache Rep. 2003;7: 55-62, and Curr Headache Rep 2003;2: 11-18.
12. Ziegler D, Ford R, Kriegler J, et al. Dihydroergotamine nasal spray for the acute treatment of migraine. Neurology. 1994;44: 447-453.
13. Shrewsbury SB, Armer TA, Newman SP, Pitcairn G. Breath-synchronized plume-control inhaler for pulmonary delivery of fluticasone propionate. Int J Pharm. 2008;356: 137-143.
14. Shrewsbury SB, Cook RO, Taylor G, Edwards C, Ramadan NM. Safety and pharmacokinetics of dihydroergotamine mesylate administered via a novel (TEMPO) inhaler. Headache. 2008;48: 355-367.
15. Berenberg E, Clemons D, Kellerman D, Kori S, Noveck RJ. A randomized, double-blind, placebo controlled, three-period crossover study comparing the acute effects of LEVADEX (MAP0004, orally inhaled DHE) and intravenous DHE on pulmonary arterial systolic pressure. Headache. 2011;51: 1-66.
16. Kellerman D, Kori S, Forst A, et al. Lack of drug interaction between the migraine drug MAP0004 (orally inhaled dihydroergotamine) and a CYP3A4 inhibitor in humans. Cephalalgia. 2011;32: 150-158.
17. Cook RO, Shrewsbury SB, Ramadan NM. Reduced adverse event profile of orally inhaled DHE (MAP0004) vs IV DHE: Potential mechanism. Headache. 2009;49: 1423-1434.
18. Kellerman DJ, Forst A, Combs DL, Borland S, Kori S. Assessment of the consistency of absorption of dihydroergotamine following oral inhalation: Pooled results from four clinical studies. J Aerosol Med Pulm Drug Deliv. 2012. (forthcoming).
19. Baron EP, Tepper SJ. Orally inhaled dihydroergotamine: Reviving and improving a classic. Future Neurol. 2011;6: 327-333.
20. Müller-Schweinitzer E,Weidmann H. Basic pharmacologic properties. In: Berde B, Schild HO, eds. Ergot Alkaloids and Related Compounds. Berlin: Springer-Verlag; 1978: 87-232.
21. Silberstein SD, McCrory DC. Ergotamine and dihydroergotamine: History, pharmacology, and efficacy. Headache. 2003;43: 144-166.
22. Humbert H, Cabiac MD, Dubray C, Lavene D. Human pharmacokinetics of dihydroergotamine administered by nasal spray. Clin Pharmacol Ther. 1996;60: 265-275.
23. Copeland RA, Pompliano DL, Meek TD. Drugtarget residence time and its implications for lead optimization. Nat Rev Drug Discov. 2006;5: 730-739.
24. Kori S, Zhang J, Kellerman D, Armer T, Goadsby PJ. Sustained pain relief with dihydroergotamine in migraine is potentially due to persistent binding to 5-HR1B and 5-HT1D receptors [poster P7]. Headache. 2012;52: 874-875, also presented at 3rd Joint Biennial Congress of European Headache and Migraine Trust International Congress London, United Kingdom Sept. 20-23, 2012 (Abstract).
25. Goadsby PJ, Gundlach AL. Localization c: 3H-dihydroergota-mine-binding sties in the cat central nervous system: Relevance to migraine. Ann Neurol. 1991;29: 91-94.
26. Aurora SK, Silberstein SD, Kori SH, et al. MAP0004, orally inhaled DHE: A randomized, controlled study in the acute treatment of migraine. Headache. 2011;51: 507-517.
27. Tepper SJ, Kori SH, Goadsby PJ, et al. MAP0004, orally inhaled DHE for the acute treatment of migraine: Efficacy of early and late treatments. Mayo Clin Proc. 2011;86: 948-955.
28. Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: A race against the development of cutaneous allodynia. Ann Neurol. 2004;55: 19-26.
29. Burstein R, Levy D, Jakubowski M. Effects of sensitization of trigeminovascular neurons to triptan therapy during migraine. Rev Neurol (Paris). 2005; 161: 658-660.
30. Tepper SJ, Kori SH, Borland SW, et al. Efficacy and safety of MAP0004, orally inhaled DHE in treating migraines with and without allodynia. Headache. 2012;52: 37-47.
31. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorder, 3rd Edition, Beta Version. Cephalalgia. 2013;33: 629-808.
32. Tepper SJ. Perimenstrual migraines: Are they different than migraines in general? Curr Pain Headache Rep. 2008;12: 463-467.
33. Aurora SK, Lu B, Connors E, Li X, Kellerman D, Kori S. Analysis of patients with menstrually related migraine vs. non-menstrually related migraine treated with MAP0004. J Headache Pain. 2013; 14(Suppl. 1): P143 (Abstract).
34. Kori S, Lu B, Connors E, Li X, Kellerman D. MAP0004 provided consistent migraine pain relief even after repeated administration. J Headache Pain. 2013;14(Suppl. 1): P190 (Abstract); also presented at PAINWeek meeting, Las Vegas, NV, September 2012 (Abstract).
35. Kori S, Lu B, Connors E, Li X, Kellerman D. Consistency of migraine pain relief after repeated administration of MAP0004. Neurology. 2013;80 (Meeting Abstracts 1): P01.086 (Abstract).
36. Kori S, Kellerman D, Chang J, Reppine A. A Long-term Open-label Study assessing the safety and tolerability of MAP0004 orally inhaled dihydroergotamine in adult migraineurs. 28th Annual Meeting of the American Academy of Pain Medicine (AAPM), Palm Springs, CA, February 23-26, 2012 (Abstract).
37. Shrewsbury SB, Kori SH, Miller SD, Pedinoff A, Weinstein S. Randomized double-blind controlled study of the safety, tolerability, and pharmacokinetics of MAP0004 (orally-inhaled DHE) in adult asthmatics. Curr Med Res Opin. 2008;24: 1977-1985.
38. Chang J, Kellerman D, Kori S, Meyer J, Zhou J, Armer T. Acute inhalation safety of MAP0004: Studies in healthy volunteers, smokers, and patients with asthma [poster P6]. Headache. 2012;52: 874 (Abstract).
39. Jividen H, Haugen G,Kellerman D,Kori S, Heyman E, Elhard M. A thorough QT study comparing supratherapeutic dose of orally inhaled DHE, moxifloxacin, and placebo on the QT interval in healthy volunteers. Headache. 2011;51(S1): 21-22 (Abstract).
40. Oguma Y, Nishimura M, Abe S, Hasegawa H, Kawakami Y, Ide H. A case of retroperitoneal fibrosis following dihydroergotamine therapy. Nippon Naika Gakkai Zasshi. 1984;7: 864-870.
41. Malaquin F, Urban T, Ostinelli J, Ghedira H, Lacronique J. Pleural and retroperitoneal fibrosis from dihydroergotamine. N Engl J Med. 1989; 321: 1760.
42. Roth BL. Drugs and valvular heart disease.N Engl J Med. 2007;356: 6-9.
43. Humphrey P. Cited in abstracts and citations. Headache. 2007;47: 940.